The company recently celebrated three decades since its founding in Albany, New York
Albany Molecular Research, (AMRI), a global CDMO for the pharmaceutical and biopharmaceutical industries, is changing its name to Curia, effective July 12, 2021. The updated name is designed to reinforce the company’s strategic positioning. Along with the name change, the company is updating its brand identity, including its website.
The name Curia is derived from a Latin word for purposeful assembly and references the company’s patient-inspired mission, it claims. It recently celebrated three decades since its founding in Albany, New York. Today, the company offers a suite of R&D and commercial manufacturing capabilities, employing more than 3,000 people in 21. The company has 564 active patents and produces more than 20 treatments included on the list of essential medicines from the World Health Organization.
“Our new name reflects the assembled deep expertise of our people, the breadth of our products, services and solutions, and our relentless determination to help customers advance from curiosity to cure,” said Curia Chairman and CEO John Ratliff. “Our new brand honors our foundation in research and innovation while creating a platform for our ambitions of life-changing science so we can make ever-growing contributions to improving patients’ lives. Over the past three decades we have broadened and deepened our capabilities to become a leading provider of CDMO solutions. Today marks the beginning of the next chapter in our history.”